Component

Type 1 diabetes

Type 1 diabetes. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. A subset of GABA-A receptor subunits are expressed by CD4-positive T cells including the delta subunit that confers high affinity for GABA and sensitivity to alcohol, GABA at relatively low concentrations down-regulated effector T cell responses to beta cell antigens ex vivo and administration of GABA retarded the adoptive transfer of type 1 diabetes in NOD/scid mice, treatment with a low dose of GABA at 600 micrograms daily dramatically inhibited the development of proinflammatory T cell responses and disease progression in disease-prone mice that already had established autoimmunity, and GABA inhibited T cell receptor-mediated T cell cycle progression in vitro which may underlie the therapeutic effects.

    Gamma-aminobutyric acid → Type 1 diabetes source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/15470076.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5523c02fc4571d5ab6c23776794b4b5cf025fb86cdba9acdc12011f3a6b2e09", "start_char": 0, "end_char": 1443, "text_sha256": "e5523c02fc4571d5ab6c23776794b4b5cf025fb86cdba9acdc12011f3a6b2e09"}
    experimental_model
    Subunit analysis with ex vivo antigen responses, adoptive transfer and treatment of disease-prone mice
    exposure
    GABA at low concentrations ex vivo, and 600 micrograms daily in mice with established autoimmunity
    limitations
    A mouse type 1 diabetes model. The cell cycle result offers a mechanism for the disease effect but is measured separately from it.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Mouse
    plain_language
    Low doses slowed the immune attack on the insulin-producing cells even after that attack had already started.
    primary_references
    [gb-p15470076] Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. (2004). https://pubmed.ncbi.nlm.nih.gov/15470076/ DOI: 10.4049/jimmunol.173.8.5298
    tissue_or_cell_type
    CD4 T cell and pancreatic islet

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 534–545

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Subunit analysis with ex vivo antigen responses, adoptive transfer and treatment of disease-prone mice · source_derived_draft · unverified_draft

    ### gb-gaba-slows-the-autoimmune-t-cell A subset of GABA-A receptor subunits are expressed by CD4-positive T cells including the delta subunit that confers high affinity for GABA and sensitivity to alcohol, GABA at relatively low concentrations down-regulated effector T cell responses to beta cell antigens ex vivo and administration of GABA retarded the adoptive transfer of type 1 diabetes in NOD/scid mice, treatment with a low dose of GABA at 600 micrograms daily dramatically inhibited the development of proinflammatory T cell responses and disease progression in disease-prone mice that already had established autoimmunity, and GABA inhibited T cell receptor-mediated T cell cycle progression in vitro which may underlie the therapeutic effects. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: Low doses slowed the immune attack on the insulin-producing cells even after that attack had already started. organism: Mouse tissue_or_cell_type: CD4 T cell and pancreatic islet experimental_model: Subunit analysis with ex vivo antigen responses, adoptive transfer and treatment of disease-prone mice limitations: A mouse type 1 diabetes model. The cell cycle result offers a mechanism for the disease effect but is measured separately from it. exposure: GABA at low concentrations ex vivo, and 600 micrograms daily in mice with established autoimmunity evidence_span: {"source_cache": "artifacts/gaba-research/15470076.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5523c02fc4571d5ab6c23776794b4b5cf025fb86cdba9acdc12011f3a6b2e09", "start_char": 0, "end_char": 1443, "text_sha256": "e5523c02fc4571d5ab6c23776794b4b5cf025fb86cdba9acdc12011f3a6b2e09"} [gb-p15470076] Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. (2004). https://pubmed.ncbi.nlm.nih.gov/15470076/ DOI: 10.4049/jimmunol.173.8.5298
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Unlike in adult brain or islet alpha-cells in which GABA exerts hyperpolarizing effects, in islet beta-cells GABA produces membrane depolarization and calcium influx leading to the activation of PI3-kinase and Akt-dependent growth and survival pathways, this provides a potential mechanism underlying findings that GABA therapy preserves beta-cell mass and prevents the development of type 1 diabetes, remarkably in severely diabetic mice GABA restores beta-cell mass and reverses the disease, and GABA suppresses insulitis and systemic inflammatory cytokine production.

    Gamma-aminobutyric acid → Pancreatic islet beta cell source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/21709230.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "926bc916592c55cf6089bcb240ec5545e0ff3850e6d927bb82efacfc61841175", "start_char": 0, "end_char": 1117, "text_sha256": "926bc916592c55cf6089bcb240ec5545e0ff3850e6d927bb82efacfc61841175"}
    experimental_model
    Islet cell electrophysiology and signalling with GABA therapy in diabetes-prone and severely diabetic mice
    exposure
    GABA given therapeutically, with membrane potential, calcium influx and survival pathway readouts in beta cells
    limitations
    A mouse therapy study. Its electrophysiological claim about beta cells is stated as a contrast with alpha cells and brain rather than shown alongside a measured chloride gradient.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Mouse
    plain_language
    In the insulin-producing cell the same molecule does the opposite of what it does in the brain, and the cells survive better for it.
    primary_references
    [gb-p21709230] GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. (2011). https://pubmed.ncbi.nlm.nih.gov/21709230/ DOI: 10.1073/pnas.1102715108
    tissue_or_cell_type
    Pancreatic islet and immune system

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 430–441

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Islet cell electrophysiology and signalling with GABA therapy in diabetes-prone and severely diabetic mice · source_derived_draft · unverified_draft

    ### gb-gaba-depolarises-the-beta-cell Unlike in adult brain or islet alpha-cells in which GABA exerts hyperpolarizing effects, in islet beta-cells GABA produces membrane depolarization and calcium influx leading to the activation of PI3-kinase and Akt-dependent growth and survival pathways, this provides a potential mechanism underlying findings that GABA therapy preserves beta-cell mass and prevents the development of type 1 diabetes, remarkably in severely diabetic mice GABA restores beta-cell mass and reverses the disease, and GABA suppresses insulitis and systemic inflammatory cytokine production. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: In the insulin-producing cell the same molecule does the opposite of what it does in the brain, and the cells survive better for it. organism: Mouse tissue_or_cell_type: Pancreatic islet and immune system experimental_model: Islet cell electrophysiology and signalling with GABA therapy in diabetes-prone and severely diabetic mice limitations: A mouse therapy study. Its electrophysiological claim about beta cells is stated as a contrast with alpha cells and brain rather than shown alongside a measured chloride gradient. exposure: GABA given therapeutically, with membrane potential, calcium influx and survival pathway readouts in beta cells evidence_span: {"source_cache": "artifacts/gaba-research/21709230.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "926bc916592c55cf6089bcb240ec5545e0ff3850e6d927bb82efacfc61841175", "start_char": 0, "end_char": 1117, "text_sha256": "926bc916592c55cf6089bcb240ec5545e0ff3850e6d927bb82efacfc61841175"} [gb-p21709230] GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. (2011). https://pubmed.ncbi.nlm.nih.gov/21709230/ DOI: 10.1073/pnas.1102715108
    Complete structured claim and evidence

  2. We studied 334 patients aged 10 to 20 years with type 1 diabetes, fasting C-peptide levels of more than 0.3 nanograms per millilitre and detectable serum GAD65 autoantibodies, randomly assigned within 3 months after diagnosis to four doses of GAD-alum, two doses followed by two doses of placebo, or four doses of placebo, the stimulated C-peptide level declined to a similar degree in all study groups and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group with P = 0.10, and the use of GAD-alum did not affect the insulin dose, glycated haemoglobin level or hypoglycaemia rate.

    Alum-formulated GAD65 antigen therapy → Stimulated serum C-peptide after a mixed-meal tolerance test source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/22296077.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "fc3bf9a083b3179c8573e993fb61f09412eca7890c3ccfb3ba5b8c0fb26acce8", "start_char": 0, "end_char": 1683, "text_sha256": "fc3bf9a083b3179c8573e993fb61f09412eca7890c3ccfb3ba5b8c0fb26acce8"}
    experimental_model
    Randomised placebo-controlled trial of an alum-formulated autoantigen in 334 patients within three months of diagnosis
    exposure
    Four doses of GAD-alum, two doses followed by placebo, or four doses of placebo, in patients aged 10 to 20 with detectable GAD65 autoantibodies
    limitations
    A properly powered randomised trial with stimulated C-peptide as the primary outcome. It tests the autoantigen as a therapy, not GABA.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Human
    plain_language
    Vaccinating against the enzyme the immune system attacks did not slow the loss of insulin production.
    primary_references
    [gb-p22296077] GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. (2012). https://pubmed.ncbi.nlm.nih.gov/22296077/ DOI: 10.1056/nejmoa1107096
    tissue_or_cell_type
    Pancreatic beta cell function

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 456–467

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomised placebo-controlled trial of an alum-formulated autoantigen in 334 patients within three months of diagnosis · source_derived_draft · unverified_draft

    ### gb-targeting-the-autoantigen-did-not-work We studied 334 patients aged 10 to 20 years with type 1 diabetes, fasting C-peptide levels of more than 0.3 nanograms per millilitre and detectable serum GAD65 autoantibodies, randomly assigned within 3 months after diagnosis to four doses of GAD-alum, two doses followed by two doses of placebo, or four doses of placebo, the stimulated C-peptide level declined to a similar degree in all study groups and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group with P = 0.10, and the use of GAD-alum did not affect the insulin dose, glycated haemoglobin level or hypoglycaemia rate. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: Vaccinating against the enzyme the immune system attacks did not slow the loss of insulin production. organism: Human tissue_or_cell_type: Pancreatic beta cell function experimental_model: Randomised placebo-controlled trial of an alum-formulated autoantigen in 334 patients within three months of diagnosis limitations: A properly powered randomised trial with stimulated C-peptide as the primary outcome. It tests the autoantigen as a therapy, not GABA. exposure: Four doses of GAD-alum, two doses followed by placebo, or four doses of placebo, in patients aged 10 to 20 with detectable GAD65 autoantibodies evidence_span: {"source_cache": "artifacts/gaba-research/22296077.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "fc3bf9a083b3179c8573e993fb61f09412eca7890c3ccfb3ba5b8c0fb26acce8", "start_char": 0, "end_char": 1683, "text_sha256": "fc3bf9a083b3179c8573e993fb61f09412eca7890c3ccfb3ba5b8c0fb26acce8"} [gb-p22296077] GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. (2012). https://pubmed.ncbi.nlm.nih.gov/22296077/ DOI: 10.1056/nejmoa1107096
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards